Research suggests that co-treatment using KRAS G12C inhibitors and IN10018 is likely to benefit cancer patients with mutated KRAS G12C and may also prevent resistance to KRAS G12C inhibition by targeting dysregulated FAK-YAP signaling and fibrogenesis [145]. This evidence concerns the gene PTK2 and cancer.